ChAdOx1 nCov-19 intranasal / University of Oxford, Imperial College London - LARVOL DELTA

AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection. (PubMed, Cell Rep Med) - P3 | "Vaccinees display a robust recall IgG response upon breakthrough infection, with overall magnitudes unaffected by time between vaccination and illness. Mucosal responses correlate with reduced viral loads and shorter durations of viral shedding in saliva."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study of Intranasal ChAdOx1 nCOV-19 (clinicaltrials.gov) - P1 | N=42 | Completed | Sponsor: University of Oxford | Recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. (PubMed, EBioMedicine) - "This formulation of intranasal ChAdOx1 nCoV-19 showed an acceptable tolerability profile but induced neither a consistent mucosal antibody response nor a strong systemic response."

Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study of Intranasal ChAdOx1 nCOV-19 (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: University of Oxford | Trial completion date: Mar 2022 ➔ Sep 2022 | Trial primary completion date: Mar 2022 ➔ Sep 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Vaccination efficacy in patients with hematological malignancies (YouTube) - "Current knowledge on whether vaccines are efficacious in patients with hematological malignancies remain limited. Susanne Saussele, MD...discusses antibody response to vaccination with BNT162b2, mRNA-1273, and ChADOx1 in patients with hematological disorders....Further research is required to assess the effect of booster vaccines in patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA."

Video

A Study of Intranasal ChAdOx1 nCOV-19 (clinicaltrials.gov) - P1; N=54; Recruiting; Sponsor: University of Oxford; Enrolling by invitation ➔ Recruiting

Clinical • Enrollment status • Infectious Disease • Novel Coronavirus Disease

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. (PubMed, Sci Transl Med) - "Intranasal vaccination of rhesus macaques resulted in reduced virus concentrations in nasal swabs and a reduction in viral loads in bronchoalveolar lavage and lower respiratory tract tissue. Intranasal vaccination with ChAdOx1 nCoV-19/AZD1222 reduced virus concentrations in nasal swabs in two different SARS-CoV-2 animal models, warranting further investigation as a potential vaccination route for COVID-19 vaccines."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. (PubMed, NPJ Vaccines) - "No vaccine-associated adverse events were observed associated with the ChAdOx1 nCoV-19 candidate, with the data from this study suggesting it could be an effective and safe vaccine against COVID-19. Our study also indicates the potential for intranasal administration as a way to further improve the efficacy of this leading vaccine candidate."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study of Intranasal ChAdOx1 nCOV-19 (clinicaltrials.gov) - P1; N=54; Enrolling by invitation; Sponsor: University of Oxford; N=30 ➔ 54; Trial completion date: Oct 2021 ➔ Feb 2022; Trial primary completion date: Oct 2021 ➔ Feb 2022

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

A Study of Intranasal ChAdOx1 nCOV-19 (clinicaltrials.gov) - P1; N=30; Enrolling by invitation; Sponsor: University of Oxford; Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Infectious Disease • Novel Coronavirus Disease